Innovent Biologics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Innovent Biologics is forecast to grow earnings and revenue by 58.7% and 22.1% per annum respectively. EPS is expected to grow by 60% per annum. Return on equity is forecast to be 15.9% in 3 years.

Wichtige Informationen

58.7%

Wachstumsrate der Gewinne

60.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum41.8%
Wachstumsrate der Einnahmen22.1%
Zukünftige Eigenkapitalrendite15.9%
Analystenabdeckung

Good

Zuletzt aktualisiert03 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Jun 14
Shareholders May Not Be So Generous With Innovent Biologics, Inc.'s (HKG:1801) CEO Compensation And Here's Why

Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 01
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Feb 28
There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump

Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Jan 12
Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?

Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

Dec 25
Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues

An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Sep 11
An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued

Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Jun 04
Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?

Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

May 14
Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price

Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Dec 27
Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate

Gewinn- und Umsatzwachstumsprognosen

SEHK:1801 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202613,4141,3531,3001,76428
12/31/202510,496105-30850630
12/31/20248,092-773-1,327-69530
6/30/20247,457-1,281-969555N/A
3/31/20246,831-1,155-1,102351N/A
12/31/20236,206-1,028-1,234148N/A
9/30/20235,612-1,198-2,241-794N/A
6/30/20235,018-1,368-3,249-1,735N/A
3/31/20234,787-1,774-3,267-1,827N/A
12/31/20224,556-2,179-3,284-1,919N/A
9/30/20224,562-2,427-3,507-1,867N/A
6/30/20224,568-2,676-3,729-1,816N/A
3/31/20224,419-2,702-3,801-1,920N/A
12/31/20214,270-2,729-3,872-2,025N/A
9/30/20214,536-2,061-2,660-1,302N/A
6/30/20214,801-1,394-1,447-580N/A
3/31/20214,323-1,196-1,138-444N/A
12/31/20203,844-998-829-308N/A
9/30/20202,765-1,306-1,307-900N/A
6/30/20201,686-1,614-1,784-1,492N/A
3/31/20201,367-1,667-1,907-1,578N/A
12/31/20191,048-1,720-2,030-1,664N/A
9/30/2019699-4,125-1,988-1,625N/A
6/30/2019351-6,530-1,945-1,586N/A
3/31/2019180-6,151-1,635-1,299N/A
12/31/20189-5,771-1,325-1,012N/A
9/30/201839-3,041-1,046-799N/A
6/30/201869-311-767-587N/A
3/31/201872-437N/A-540N/A
12/31/201775-562N/A-492N/A
12/31/201629-504N/A-363N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1801 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Ertrag vs. Markt: 1801 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hohe Wachstumserträge: 1801 is expected to become profitable in the next 3 years.

Einnahmen vs. Markt: 1801's revenue (22.1% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Hohe Wachstumseinnahmen: 1801's revenue (22.1% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 1801's Return on Equity is forecast to be low in 3 years time (15.9%).


Wachstumsunternehmen entdecken